Print
Email
Print Edition StoriesThursday, March 11, 2010
Agios appoints Kaelin to scientific advisory board
By Mass High Tech staff
MHT talks with Christopher Lambert of WPI Center for Neuroprosthetics
MHT's Julie Donnelly: Pharmaceuticals find drug development partners in colleges
Funding drugs for rare diseases
Agios Pharmaceuticals Inc., a Cambridge biopharmaceutical firm focused on drugs associated with cancer metabolism, has named Dr. William Kaelin to its scientific advisory board.
Kaelin is a professor of medicine at Harvard Medical School; his laboratory is researching tumor suppressor genes and the proteins they encode. He previously served as a medical oncology clinical fellow at Dana Farber Cancer Institute and a postdoctoral fellow in Dr. David Livingston’s laboratory. Kaelin earned his M.D. from Duke University.
The field of cancer metabolism concentrates on cell growth within cancer cells, which rely on more nutrients than normal cells to survive, Agios officials report.
Agios Pharmaceuticals was founded by cell metabolism leaders Lewis C. Cantley, director of the Cancer Center at Beth Israel Deaconess Medical Center and professor of systems biology at Harvard Medical School; Tak W. Mak, of The Campbell Family Institute for Cancer Research and The University of Toronto; and Craig B. Thompson, director of the Abramson Cancer Center, University of Pennsylvania.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
